Note 2 - Revenue

12 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Revenue from Contract with Customer [Text Block]

2.

Revenue

The following tables present the Company’s revenues disaggregated by type:

	Year ended December 31,
(in thousands)	2019		2018
Revenue
Product	$	69,763	$	54,687
Service		3,947		5,066
Total revenue	$	73,710	$	59,753

The following tables reflect revenue by geography (United States, Europe and rest of world, or Europe and ROW, and Asia):

	Year ended December 31,
(in thousands, except percentages)	2019				2018
Revenue
United States	$	24,177	33	%	$	16,442	28	%
Europe and ROW		10,421	14	%		9,153	15	%
Asia		39,112	53	%		34,158	57	%
Total revenue	$	73,710	100	%	$	59,753	100	%

In the year ended

December 31, 2019

, the Company had

four

 customers that represented more than

10%

of the Company’s total annual revenue. The Company’s former Chinese distributor, Fosun, represented

15%

of total annual r

evenue. In

December 2019,

the Company entered into a new non-exclusive distribution agreement with Shanghai Pharma, which represented

15%

of

2019

revenue. The Company’s Japanese importer, Riken, represented

15%

of total annual revenue. In the U

.S., Quest accounted for

27%

of the Company's total annual revenue.

Revenue from Shanghai Pharma is variable and depends on their margin, along with various other items that can only be determined subsequent to the Company’s shipment of products to them, and is only recognized in income to the extent management considers it is

not

constrained. Variable consideration estimates will be re-assessed at each reporting period until a final outcome is determined.